|
Gene: PHYHIPL |
Gene summary for PHYHIPL |
Gene summary. |
Gene information | Species | Human | Gene symbol | PHYHIPL | Gene ID | 84457 |
Gene name | phytanoyl-CoA 2-hydroxylase interacting protein like | |
Gene Alias | PHYHIPL | |
Cytomap | 10q21.1 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q96FC7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84457 | PHYHIPL | HCC1_Meng | Human | Liver | HCC | 1.51e-06 | -3.29e-02 | 0.0246 |
84457 | PHYHIPL | HCC1 | Human | Liver | HCC | 7.94e-12 | 4.86e+00 | 0.5336 |
84457 | PHYHIPL | HCC2 | Human | Liver | HCC | 6.16e-09 | 2.40e+00 | 0.5341 |
84457 | PHYHIPL | S014 | Human | Liver | HCC | 2.27e-40 | 1.27e+00 | 0.2254 |
84457 | PHYHIPL | S015 | Human | Liver | HCC | 5.31e-32 | 1.56e+00 | 0.2375 |
84457 | PHYHIPL | S016 | Human | Liver | HCC | 2.72e-47 | 1.58e+00 | 0.2243 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PHYHIPL | SNV | Missense_Mutation | c.705N>T | p.Glu235Asp | p.E235D | Q96FC7 | protein_coding | tolerated(0.09) | probably_damaging(0.994) | TCGA-BK-A0C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PHYHIPL | SNV | Missense_Mutation | c.480C>A | p.Asp160Glu | p.D160E | Q96FC7 | protein_coding | tolerated(0.43) | possibly_damaging(0.751) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PHYHIPL | SNV | Missense_Mutation | novel | c.470G>A | p.Cys157Tyr | p.C157Y | Q96FC7 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.646) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
PHYHIPL | SNV | Missense_Mutation | rs776129253 | c.236G>A | p.Arg79His | p.R79H | Q96FC7 | protein_coding | deleterious_low_confidence(0.05) | benign(0.07) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PHYHIPL | SNV | Missense_Mutation | novel | c.959T>G | p.Leu320Arg | p.L320R | Q96FC7 | protein_coding | tolerated(0.22) | possibly_damaging(0.732) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PHYHIPL | SNV | Missense_Mutation | rs745453654 | c.926N>C | p.Lys309Thr | p.K309T | Q96FC7 | protein_coding | tolerated(0.24) | benign(0.073) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PHYHIPL | deletion | Frame_Shift_Del | novel | c.780delT | p.Phe260LeufsTer22 | p.F260Lfs*22 | Q96FC7 | protein_coding | TCGA-A5-A0GH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
PHYHIPL | insertion | Nonsense_Mutation | novel | c.559_560insGAAATTAGAGATACTG | p.Tyr187Ter | p.Y187* | Q96FC7 | protein_coding | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
PHYHIPL | insertion | Frame_Shift_Ins | novel | c.953_954insCTGTATTCTA | p.Val319CysfsTer21 | p.V319Cfs*21 | Q96FC7 | protein_coding | TCGA-D1-A0ZP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD | ||
PHYHIPL | SNV | Missense_Mutation | novel | c.1028N>C | p.Gly343Ala | p.G343A | Q96FC7 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-DD-AAD0-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |